MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in CanadaGlobeNewsWire • 01/11/23
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in BrazilGlobeNewsWire • 01/10/23
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)GlobeNewsWire • 01/05/23
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes FederationGlobeNewsWire • 12/06/22
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol AbuseGlobeNewsWire • 12/05/22
MediciNova to Participate in the Lytham Partners Fall 2022 Investor ConferenceGlobeNewsWire • 09/15/22
MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of GlioblastomaGlobeNewsWire • 09/14/22
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in CanadaGlobeNewsWire • 09/13/22
MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVIDGlobeNewsWire • 08/16/22
MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes FederationGlobeNewsWire • 08/09/22
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in KoreaGlobeNewsWire • 07/27/22
MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and HypertriglyceridemiaGlobeNewsWire • 07/26/22
MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)GlobeNewsWire • 07/21/22
MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung InjuryGlobeNewsWire • 06/29/22
MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, JapanGlobeNewsWire • 06/22/22
MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress SyndromeGlobeNewsWire • 06/08/22
MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer ResearchGlobeNewsWire • 04/20/22
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress SyndromeGlobeNewsWire • 04/13/22
MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and HypertriglyceridemiaGlobeNewsWire • 04/11/22
MediciNova's Alcohol Use Disorder Candidate Reduces Alcohol Craving, Odds Of Heavy DrinkingBenzinga • 04/08/22
MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental ResearchGlobeNewsWire • 04/07/22
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in KoreaGlobeNewsWire • 03/17/22
MediciNova to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-VestGlobeNewsWire • 03/15/22